Procurement of DUPILUMAB SC 300MG/2ML INJ SOL CAN, AUE no. 202600403, from Lab. Sanofi, for ULSASI, for the year 2026

This tender concerns the acquisition of DUPILUMAB SC 300MG/2ML INJ SOL CAN, a subcutaneous injection formulation of Dupilumab. Dupilumab is a monoclonal antibody used to treat inflammatory conditions such as moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. The procurement is authorized under Approved Unique Estimate (AUE) number 202600403 and specifies Sanofi as the supplying laboratory. The intended recipient is ULSASI, and the supply is for the year 2026. This acquisition is crucial for ULSASI to provide advanced biologic therapies to patients suffering from chronic inflammatory diseases, ensuring access to effective treatments that can significantly improve quality of life.

This is a supplies contract in the health and medical services, Research and general supplies sectors, with a focus on Laboratories. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 13,867.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.